Cerebrovascular Reserve Measurements in Sickle Cell Disease

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary aim of this study is to evaluate MRI-based cerebrovascular reserve (CVR) measurements in adult patients with Sickle Cell Disease (SCD).

The primary objective is to assess whether there is a correlation between CVR and silent cerebral infarcts (SCIs).

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
• Treatments: Acetazolamide

Criteria

Inclusion Criteria Patient group:

• Sickle cell disease; either homozygous sickle cell disease (HbSS), or HbSβ0 thalassemia

• 18 years of age or older

• Informed consent

Inclusion Criteria Control group:

• Similar ethnic background as Patient group

• 18 years of age or older

• Informed consent

Exclusion Criteria Patient group and Control group:

• Inability of the patient to provide informed consent or legally incompetent/incapacitated to do so

• Contraindications for MRI, such as pregnancy, claustrophobia or the presence of metal in the body

• Sickle cell crisis at the moment of participation

• History of cerebral pathology that compromises measurements, such as cerebral palsy, brain tumour,meningitis, overt infarct

• Brain surgery performed in the last 3 months

• Severe liver, heart or renal dysfunction (clearance < 10 mL/min)

• Allergy to sulphonamide

• Breastfeeding

• Use of phenytoin, procaine or acetylsacylic acid ("Ascal/aspirin")

• Risk of hypokalaemia (use of diuretics, primary hyperaldosteronism)

• Addison's Disease

• Severe asthma or emphysema